President Trump considers imposing retaliatory economic sanctions on Chinese products.

Peter Prince

2018-01-10 08:40:00 Wed ET

President Trump considers imposing retaliatory economic sanctions on Chinese products and services in direct response to China's theft and infringement of U.S. intellectual property. Trump's retaliatory trade sanctions may involve tariffs, quotas, embargoes, and other restrictions on China's investments in U.S. companies. This punitive penalty arises as part of a recent Trade Act Section 301 probe into China's recent regulations that induce U.S. multinational corporations to establish onshore IT data centers. These regulations force unfair intellectual property and technology transfer from these U.S. multinational corporations to their Chinese counterparts. Without such technology transfer, the use and implementation of U.S. patents and trademarks would otherwise involve egregious infringement at the expense of U.S. firms and other innovators.

Recent empirical evidence suggests that this unfair technology transfer may be the root cause of both billions of dollar losses in corporate revenue as well as millions of job losses in America. In addition to intellectual property theft and infringement, the Trump administration also accuses China of currency manipulation. Over the years, China has been accumulating substantial dollar reserves in the form of U.S. Treasury bonds for better renminbi devaluation. This deliberate devaluation leads to more competitive Chinese export prices and thus better low-cost product sales abroad. The Trump administration needs to consider retaliatory trade sanctions on China in order to eradicate trade deficits with better fiscal discipline.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Goldman Sachs chief economist Jan Hatzius proposes designing a new Financial Conditions Index (FCI).

Chanel Holden

2018-07-19 18:38:00 Thursday ET

Goldman Sachs chief economist Jan Hatzius proposes designing a new Financial Conditions Index (FCI).

Goldman Sachs chief economist Jan Hatzius proposes designing a new Financial Conditions Index (FCI) to be a weighted-average of interest rates, exchange rat

+See More

Presidents Trump and Xi agree on an interim trade truce at the G20 summit in Argentina.

Apple Boston

2018-12-09 08:44:00 Sunday ET

Presidents Trump and Xi agree on an interim trade truce at the G20 summit in Argentina.

President Trump meets with Chinese President Xi again at the G20 summit in the city of Buenos Aires, Argentina, in late-November 2018. President Donald Trum

+See More

House of Representatives considers a government expenditure bill with border wall finance and so sets up a shutdown stalemate with Senate.

Laura Hermes

2018-12-23 13:39:00 Sunday ET

House of Representatives considers a government expenditure bill with border wall finance and so sets up a shutdown stalemate with Senate.

The House of Representatives considers a government expenditure bill with border wall finance and therefore sets up a shutdown stalemate with Senate. As fre

+See More

Platforms benefit from positive network effects, scale economies, and information cascades.

Rose Prince

2019-07-25 16:42:00 Thursday ET

Platforms benefit from positive network effects, scale economies, and information cascades.

Platforms benefit from positive network effects, scale economies, and information cascades. There are at least 2 major types of highly valuable platforms: i

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

The Economist highlights a trifecta of plausible explanations for better economic fortunes during the current Trump administration.

Chanel Holden

2018-08-27 09:35:00 Monday ET

The Economist highlights a trifecta of plausible explanations for better economic fortunes during the current Trump administration.

President Trump and his Republican senators and supporters praise the recent economic revival of most American counties. The Economist highlights a trifecta

+See More